High-dose vitamin D shows benefit in patients with advanced colorectal cancer
Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with…
Read more
Alnylam looks to next RNAi approval, but safety questions linger
Alnylam on Friday released full results from a pivotal Phase 3 study for givosiran, setting the stage for the company to finish a…
Clovis throws in the towel on solo Rubraca study in bladder cancer
Bladder cancer is tough to conquer, and Clovis Oncology just got a reminder of that. The company stopped a Rubraca trial…
Almac Group Publishes Comparison Report on Automated vs Paper based Accountability & Reconciliation
Cost analysis findings include savings of over $1 million per trial Souderton, PA, USA, 8 April 2019 – Almac Clinical Technologies,…
Reformulated epileptic drug reaches first clinical trial for medically refractory epilepsy
A currently approved epileptic drug to treat seizures has been modified by a University of Colorado Anschutz Medical Campus professor…
New clinical trials to investigate combination immunotherapy for treating advanced cancers
City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be…
Sangamo hemophilia A progress boosts shares
An experimental gene therapy for hemophilia A helped to restore activity of an essential blood-clotting protein in several patients with…
United Therapeutics tosses out esuberaprost after trial flop
United Therapeutics is throwing its pulmonary arterial hypertension drug esuberaprost on the scrap heap after failing in a phase 3…
Pfizer wins expanded Ibrance approval using real world data
Pfizer on Thursday secured an expanded U.S. approval for its breast cancer drug Ibrance to men, relying not on clinical study but…
No return for the Merrimack
Merrimack Pharmaceuticals is shelving yet another lead candidate after a review of Phase 1 safety data found the drug wasn’t going to…